> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sanofi Lifts 2026 Outlook As Dupixent Sales Jump 34.8% To €5.7 Billion
- URL: https://www.bullished.co/sanofi-lifts-2026-outlook-as-dupixent-sales-jump-34-8-to-5-7-billion-232848f3/
- Published: 2026-10-30T12:56:47.000Z
- Updated: 2026-10-30T12:56:47.000Z
- Description: The drugmaker now sees low-teens sales growth and mid-teens business EPS growth at constant rates, with third-quarter business EPS at €3.55.
- Author: Matteo Parrino
- Tags: Earnings, SNY, Industry: Healthcare

Sanofi, the biopharma company behind the Dupixent antibody, raised its 2026 guidance on Friday after third-quarter sales reached [€14,444 million](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm?ref=bullished.co), up 14.3% at constant exchange rates and 16.2% at actual rates. Business EPS, the company's adjusted per-share earnings, rose to €3.55, up 19.6% at constant rates and 22.0% at actual rates.

## Higher guidance for the year

Sanofi now expects 2026 sales to grow by a low-teens percentage at constant exchange rates, and business EPS to grow by a mid-teens percentage. Currency is estimated to cut about 1% from each, using October average rates, the company said in its release.

Business operating income was [€5,430 million](https://www.globenewswire.com/news-release/2026/10/30/3392028/0/en/press-release-q3-2026-double-digit-growth-in-sales-and-business-eps-fy-2026-guidance-upgraded.html?ref=bullished.co), up 22.2% at actual rates and 19.7% at constant rates. Under standard IFRS accounting, EPS was €2.52\. Free cash flow came to €3,269 million for the quarter.

For the first nine months, sales were [€36,550 million](https://www.globenewswire.com/news-release/2026/10/30/3392028/0/en/press-release-q3-2026-double-digit-growth-in-sales-and-business-eps-fy-2026-guidance-upgraded.html?ref=bullished.co) and business EPS was €7.52\. IFRS net income for the period was €4,979 million, down 42.2%, in a year that included a €952 million impairment on the amlitelimab intangible asset booked in the second quarter.

## Dupixent above €5 billion again

Dupixent sales [rose 34.8%](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm?ref=bullished.co) to €5,687 million, above €5 billion in a quarter for the second time. US sales climbed 40.2% to €4,376 million, helped by strong demand and favourable gross-to-net price adjustments, the company said. Sanofi develops Dupixent with Regeneron, and higher profit sharing with the partner weighed on operating income.

Sales of newer launches grew 31.4% to [€1.4 billion](https://markets.ft.com/data/announce/detail?dockey=1330-1001280793en-0J5QMCPMN37NGNA82DDRQR2PFG&ref=bullished.co), led by ALTUVIIIO, Ayvakit and Rezurock.

Vaccines sales fell 6.6% to €3.2 billion on what Sanofi called anticipated phasing, with a higher share of seasonal influenza deliveries shifting to the fourth quarter. Beyfortus US sales dropped 39.3% on a lower central order from the Centers for Disease Control and Prevention.

## Life after Dupixent

CEO Belén Garijo said the whole organisation is focused on managing Sanofi's post-Dupixent trajectory over the next decade. "Our priority is to [protect earnings](https://www.globenewswire.com/news-release/2026/10/30/3392028/0/en/press-release-q3-2026-double-digit-growth-in-sales-and-business-eps-fy-2026-guidance-upgraded.html?ref=bullished.co) through Dupixent's loss of exclusivity," she said, adding that business development and M&A will be critical.

During the quarter Sanofi expanded its Regeneron alliance to add four long-acting antibodies, paying $1 billion upfront with up to $7 billion more in potential milestones. It also agreed with Cheplapharm to hand over 20 mature medicines in return for a 26.4% stake in the company.

Sanofi's US-listed shares closed at $43.13 on Thursday, before the release, giving a market value of $103.3 billion. The company reports fourth-quarter results on Thursday, January 28, 2027.

Sanofi will report fourth-quarter 2026 results on Thursday, January 28, 2027.

### Sources

- [Form 6-K — Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm?ref=bullished.co) — SEC EDGAR
- [Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance](https://finance.yahoo.com/healthcare/articles/sanofi-q3-earnings-blow-past-072257858.html?ref=bullished.co) — Yahoo Finance
- [Sanofi lifts profit outlook on strong Dupixent sales (SNY:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4661180-sanofi-lifts-profit-outlook-on-strong-dupixent-sales?ref=bullished.co) — seekingalpha.com
- [Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded | Nasdaq](https://www.nasdaq.com/press-release/press-release-q3-2026-double-digit-growth-sales-and-business-eps-fy-2026-guidance?ref=bullished.co) — nasdaq.com
- [Press Release: Q3 2026: double-digit growth in sales and](https://www.globenewswire.com/news-release/2026/10/30/3392028/0/en/press-release-q3-2026-double-digit-growth-in-sales-and-business-eps-fy-2026-guidance-upgraded.html?ref=bullished.co) — globenewswire.com
- [Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=1330-1001280793en-0J5QMCPMN37NGNA82DDRQR2PFG&ref=bullished.co) — Financial Times